tbuckley/cabot-search huggingface dataset:
Tumor Cell Dynamics: Microenvironmental Stiffness of 3D Polymeric Structures to Study Invasive Rates of Cancer Cells (Adv. Healthcare Mater. 22/2017)
Authors: Enrico Domenico Lemma, Barbara Spagnolo, Francesco Rizzi, Stefania Corvaglia, Marco Pisanello, Massimo De Vittorio, Ferruccio Pisanello
Journal: Advanced Healthcare Materials (2017)

Three-dimensional cage-like microscaffolds with tailored Young's modulus are used to induce different invasive behaviours of cancer cells according to structural stiffness by Enrico Domenico Lemma, Ferruccio Pisanello, and co-workers in article number 1700888. Tumor cells invasion is boosted by softer architectures and by the presence of stiffness “weak spots” within overall rigid scaffolds, enabling more detailed analysis on mechanical interactions between tumor cells and the extracellular matrix.
Abstract 12151: PCSK9 Mediates Atherogenesis
Authors: Hua Sun, Ronald M Krauss, Ba-bie Teng
Journal: Circulation (2016)

Background: Proprotein convertase subtilisin kexin type 9 (PCSK9) negatively regulates the low-density lipoprotein (LDL) receptor (LDLR), resulting in increased LDL cholesterol levels. We have suggested that PCSK9 regulates apolipoprotein B (apoB) metabolism via an autophagic process that is independent of the LDLR. Furthermore, whether PCSK9 plays a causal role in atherogenesis independent of LDLR has been controversial. Here, we investigated the molecular mechanisms by which PCSK9 modulates autophagy and the LDLR-independent effects of PCSK9 on atherogenesis. Methods and Results: Deletion of the PCSK9 gene from atherosclerosis prone LDb ( Ldlr-/-Apobec1-/-) mice resulted in substantially less atherosclerosis (&gt; 4-fold), as well as a substantial reduction of plasma apoB, lipids, and triglyceride-rich lipoproteins, but increased HDL particles. The triple knockout mice had a decreased rate of apoB secretion resulting from increased autophagic flux. The deletion of PCSK9 also had profound influences on aortic endothelial cell response to exposure to LDL. LDL associated with PCSK9 increased the expression of TLR2, Lox-1, ICAM-1, CCL2, CCL7, IL-6, IL-1β, Beclin-1, p62, and TRAF6, compared to LDL without PCSK9. Conclusion: Deletion of PCSK9 markedly decreases apoB production by increasing autophagic flux. The absence of PCSK9 results in decreased lipid levels and marked reduction of atherosclerosis, independent of LDLR. The influence on atherogenesis is in part due to the direct effects of PCSK9 on endothelial cell receptors and on proinflammatory and autophagy molecules. These findings suggest that there may be clinical benefits of PCSK9 inhibition due to mechanisms unrelated to increased LDLR activity.
Impact of KRAS mutational status and primary tumor location on the efficacy of aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer: An exploratory analysis in a phase II study
Authors: K. Yamazaki, T. Satoh, Y. Komatsu, T. Taguchi, Y. Sunaga, T. Yoshino
Journal: Annals of Oncology (2017)
Sex Dimorphism in the Myocardial Response to Aortic Stenosis
Authors: Thomas A. Treibel, Rebecca Kozor, Marianna Fontana, Camilla Torlasco, Patricia Reant, Sveeta Badiani, Maria Espinoza, John Yap, Javier Diez, Alun D. Hughes, Guy Lloyd, James C. Moon
Journal: JACC. Cardiovascular imaging (2017)

The goal of this study was to explore sex differences in myocardial remodeling in aortic stenosis (AS) by using echocardiography, cardiac magnetic resonance (CMR), and biomarkers. AS is a disease of both valve and left ventricle (LV). Sex differences in LV remodeling are reported in AS and may play a role in disease phenotyping. This study was a prospective assessment of patients awaiting surgical valve replacement for severe AS using echocardiography, the 6-min walking test, biomarkers (high-sensitivity troponin T and N-terminal pro–brain natriuretic peptide), and CMR with late gadolinium enhancement and extracellular volume fraction, which dichotomizes the myocardium into matrix and cell volumes. LV remodeling was categorized into normal geometry, concentric remodeling, concentric hypertrophy, and eccentric hypertrophy. In 168 patients (age 70 ± 10 years, 55% male, indexed aortic valve area 0.40 ± 0.13 cm2/m2, mean gradient 47 ± 4 mm Hg), no sex or age differences in AS severity or functional capacity (6-min walking test) were found. CMR captured sex dimorphism in LV remodeling not apparent by using 2-dimensional echocardiography. Normal geometry (82% female) and concentric remodeling (60% female) dominated in women; concentric hypertrophy (71% male) and eccentric hypertrophy (76% male) dominated in men. Men also had more evidence of LV decompensation (pleural effusions), lower left ventricular ejection fraction (67 ± 16% vs. 74 ± 13%; p < 0.001), and higher levels of N-terminal pro–brain natriuretic peptide (p = 0.04) and high-sensitivity troponin T (p = 0.01). Myocardial fibrosis was higher in men, with higher focal fibrosis (late gadolinium enhancement 16.5 ± 11.2 g vs. 10.5 ± 8.9 g; p < 0.001) and extracellular expansion (matrix volume 28.5 ± 8.8 ml/m2 vs. 21.4 ± 6.3 ml/m2; p < 0.001). CMR revealed sex differences in associations between AS and myocardial remodeling not evident from echocardiography. Given equal valve severity, the myocardial response to AS seems more maladaptive in men than previously reported. (Regression of Myocardial Fibrosis After Aortic Valve Replacement [RELIEF-AS]; NCT02174471)
Pre-Transplant Colonization By a Multidrug-Resistant Gram Negative Bacteria Has No Impact on Overall Survival and Mortality after Hematopoietic Stem Cell Transplantation: A Single-Center Experience in 362 Patients
Authors: Vincenzo Marasco, Alessandra Forcina, Francesca Lorentino, Raffaella Greco, Mara Morelli, Fabio Giglio, Carlo Messina, Maria Teresa Lupo Stanghellini, Carrabba Matteo, Magda Marcatti, Attilio Bondanza, Massimo Bernardi, Jacopo Peccatori, Consuelo Corti, Fabio Ciceri
Journal: Blood (2016)
Rubella Vaccine—A Tale of Appropriate Caution and Remarkable Success
Authors: Laura A. Zimmerman, Susan E. Reef, Walter A. Orenstein
Journal: JAMA Pediatrics (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Blf/ukpin Consensus Statement On The Definition, Diagnosis And Management Of Granulomatous-Lymphocytic Interstitial Lung Disease (glild) In Common Variable Immunodeficiency Disorders (cvid)
Authors: Hurst, N Verma, D Lowe, H E Baxendale, S Jolles, P Kelleher, H J Longhurst, S Y Patel, E A Renzoni, C R Sander, A M Condliffe, Team Blfukpin.
Journal: American Journal of Respiratory and Critical Care Medicine (2017)
A phase I trial of afatinib (Afa) and bevacizumab (Bev) in chemo-naïve patients (pts) with advanced non-small-cell lung cancer (NSCLC) harboring EGFR-mutations: OLCSG1404
Authors: D. Harada, N. Nogami, T. Kozuki, T. Ninomiya, A. Bessho, S. Kuyama, N. Fujimoto, K. Sugimoto, K. Aoe, N. Ochi, D. Minami, N. Fukamatsu, K. Kudo, K. Kiura
Journal: Annals of Oncology (2017)
The E3 Ligase RING1 Targets p53 for Degradation and Promotes Cancer Cell Proliferation and Survival
Authors: Jiajia Shen, Pengyu Li, Xuejing Shao, Yang Yang, Xiujun Liu, Min Feng, Qiang Yu, Ronggui Hu, Zhen Wang
Journal: Cancer Research (2017)

As a component of the transcriptional repression complex 1 (PRC1), the ring finger protein RING1 participates in the epigenetic regulation in cancer. However, the contributions of RING1 to cancer etiology or development are unknown. In this study, we report that RING1 is a critical negative regulator of p53 homeostasis in human hepatocellular and colorectal carcinomas. RING1 acts as an E3 ubiquitin (Ub) ligase to directly interact with and ubiquitinate p53, resulting in its proteasome-dependent degradation. The RING domain of RING1 was required for its E3 Ub ligase activity. RING1 depletion inhibited the proliferation and survival of the p53 wild-type cancer cells by inducing cell-cycle arrest, apoptosis, and senescence, with only modest effects on p53-deficient cells. Its growth inhibitory effect was partially rescued by p53 silencing, suggesting an important role for the RING1-p53 complex in human cancer. In clinical specimens of hepatocellular carcinoma, RING1 upregulation was evident in association with poor clinical outcomes. Collectively, our results elucidate a novel PRC1-independent function of RING1 and provide a mechanistic rationale for its candidacy as a new prognostic marker and/or therapeutic target in human cancer.Significance: These results elucidate a novel PRC1-independent function of RING1 and provide a mechanistic rationale for its candidacy as a new prognostic marker and/or therapeutic target in human cancer. Cancer Res; 78(2); 359-71. ©2017 AACR.
A framework for education and advocacy for optimal cancer pain management in resource-limited settings
Authors: M.J. Bautista, S.H. Ahmedzai, K. Bouzid, R. Gibson, Y. Gumara, A.A.I. Hassan, S. Hattori, D. Keefe, D.C. Kraychete, D.H. Lee, K. Tamura, J.J. Wang
Journal: Annals of Oncology (2017)
Usefulness of Total 12-Lead QRS Voltage as a Clue to Diagnosis of Patients With Cardiac Sarcoidosis Severe Enough to Warrant Orthotopic Heart Transplant
Authors: William C. Roberts, Tiffany M. Becker, Shelley A. Hall
Journal: JAMA Cardiology (2017)

Severe heart failure caused by cardiac sarcoidosis is difficult to diagnosis without biopsy.To assess whether total electrocardiographic 12-lead QRS voltage may be a clue to diagnosis.Case-series study with cases collected at Baylor University Medical Center at Dallas, Dallas, Texas, from January 13, 2005, to January 24, 2017. The clinical records of 16 patients with severe heart failure caused by cardiac sarcoidosis were studied. Examination of total 12-lead electrocardiographic QRS voltage (peak of the R wave to the nadir of either the Q or S wave, whichever was deeper) was performed prior to orthotopic heart transplant (OHT). Gross and microscopic pathologic specimens of the native hearts were studied.The primary outcome was to correlate the total 12-lead QRS voltage measurement with various morphologic features in the native diseased heart.The 16-patient study group consisted of 8 men and 8 women; 12 (75%) were white and 4 (25%) were black. At the time of OHT, patient age ranged from 50 to 67 years (mean, 57 years). Cardiac sarcoidosis was diagnosed by pre-OHT biopsy results in 2 (13%) patients and by examination of the native heart after OHT in 14 (87%) patients. Total nonpaced 12-lead QRS voltage mean was 117 mm (range, 52-155 mm) for 8 patients and total paced 12-lead QRS voltage was 90 mm (range, 67-161 mm) for 12 patients. These low mean values were similar to those of patients with carcinoid heart disease (mean [SD], 105 [40] mm), cardiac amyloidosis (104 [35] mm), and severe cardiac adiposity (120 [31] mm) studied at necropsy or after OHT. In contrast, mean (SD) values were 323 (109) mm in patients with massive cardiomegaly, 257 mm in patients with severe aortic stenosis, 272 (86) mm in patients with severe pure aortic regurgitation, 220 (67) mm in patients with severe pure mitral regurgitation, 197 (64) mm in patients with hypertrophic cardiomyopathy, and 153 (40) mm in patients with idiopathic dilated cardiomyopathy.Most patients diagnosed with cardiac sarcoidosis causing severe heart failure and warranting OHT had low total 12-lead QRS voltage measurements despite having native hearts of increased weight. This finding may provide a clue to the diagnosis of this disease.
Human-like machines: Transparency and comprehensibility
Authors: Piotr M. Patrzyk, Daniela Link, Julian N. Marewski
Journal: Behavioral and Brain Sciences (2017)

Artificial intelligence algorithms seek inspiration from human cognitive systems in areas where humans outperform machines. But on what level should algorithms try to approximate human cognition? We argue that human-like machines should be designed to make decisions in transparent and comprehensible ways, which can be achieved by accurately mirroring human cognitive processes.
A T Cell Receptor Locus Harbors a Malaria-Specific Immune Response Gene
Authors: Natalija Van Braeckel-Budimir, Stephanie Gras, Kristin Ladell, Tracy M. Josephs, Lecia Pewe, Stina L. Urban, Kelly L. Miners, Carine Farenc, David A. Price, Jamie Rossjohn, John T. Harty
Journal: Immunity (2017)
FCγRIIa and FCγRIIIa single nucleotide polymorphisms (SNPs) and cetuximab benefit in the EXCITE trial
Authors: F. Sclafani, S. Gollins, D. Cunningham, S. Hulkki Wilson, K. Kouvelakis, A. Lopes, N. West, P. Quirke, R. Begum, N. Valeri, S. Beare, L. Hughes, D. Gonzalez De Castro, I. Chau
Journal: Annals of Oncology (2017)
Stereotactic body radiation therapy for palliative treatment of bone metastases: Practice patterns and survival outcomes.
Authors: Catherine Lee Kinchen, Trent N Taylor, Candice Aitken Johnstone, Jared R. Robbins
Journal: Journal of Clinical Oncology (2017)

242 Background: Stereotactic body radiation therapy (SBRT) is an emerging modality of treatment designed to deliver high radiation doses in few fractions. We examine practice trends in the use of SBRT for managing bone metastases in patients with breast, kidney, non-small-cell lung, melanoma, or prostate cancer. Methods: We selected patients from the National Cancer Database (2004-2013) diagnosed with bone metastases from breast, kidney, non-small-cell lung, melanoma, or prostate cancer. SBRT fractionation regimens were defined as 12-45 Gy in 1 fraction, 14-50 Gy in 2 fractions, 21-50 Gy in 3 fractions, 28-50 Gy in 4 fractions, and 30-60 Gy in 5 fractions. Standard palliative radiation fractionation regimens were defined as all other cases with 2-40 Gy in 20 fractions or fewer. Results: Patients receiving SBRT regimens made up 1454 of 57,556 total palliative cases. Bone metastases treated with SBRT primarily at the spine (65.5%), hip/pelvis (12.3%), and shoulder/extremity (11.4%). SBRT palliation regimens were used for only 2.5% of patients. Though standard palliative radiation fractionation regimens comprised the majority of treatments (97.5%), SBRT utilization is increasing, with a majority (68.4%) of SBRT cases occurring from 2009-2013. Treatment at an academic center and lack of comorbidities were positively associated with receiving SBRT regimens. Mean survival outcomes were higher for patients receiving SBRT (24.3 months) than patients receiving standard regimens (16.9 months). Conclusions: Though the vast majority of bone metastases were treated with standard palliative radiation fractionation, SBRT utilization increased from 2004-2013, with the greatest portion of SBRT cases occurring at academic institutions. Patients receiving SBRT exhibit better survival outcomes, likely as a result of patient selection practices.
Abstract 16941: Device Therapies Among Patients Receiving Primary Prevention Implantable Cardioverter Defibrillators (ICDs): Insights From the Cardiovascular Research Network Longitudinal Study of ICDs
Authors: Robert T Greenlee, Alan S Go, David J Magid, Pamela N Peterson, Andrea E Cassidy-Bushrow, Charles Gaber, Romel Garcia-Montilla, Karen A Glenn, Nigel Gupta, Jerry H Gurwitz, Stephen C Hammill, John J Hayes, Alan Kadish, David D McManus, Deborah Multerer, J. David Powers, Liza M Reifler, Kristi Reynolds, Claudio Schuger, Param P Sharma, David H Smith, Mary Suits, Sue Hee Sung, Paul D Varosy, Humberto J Vidaillet, Frederick A Masoudi
Journal: Circulation (2015)

Introduction: Primary prevention implantable cardioverter defibrillators (ICDs) reduce mortality in select patients with left ventricular systolic dysfunction (LVSD). The occurrence of device therapies after ICD implantation in contemporary clinical practice is not well described, especially in patient subgroups designated in the Centers for Medicare and Medicaid Services (CMS) 2005 Coverage with Evidence Development (CED). Methods: The Longitudinal Study of ICDs assessed rates and correlates of device therapies (overall and those requiring shock) up to 3 years post-implant among 2540 patients with LVSD receiving first-time primary prevention ICDs in 7 US health care systems from 2006-2009. Implant data from the National Cardiovascular Data Registry ICD Registry were linked to electronic longitudinal health care system data and a novel centrally adjudicated repository of device therapies abstracted from medical records. Proportional hazard models evaluated associations with device therapies by appropriateness, adjusted for demographic and clinical factors. Results: Subjects were 26% women, 35% &lt;65 years old, and 59% non-Hispanic white. Over a mean 26 months, 738 (29.1%) received at least 1 therapy (median 2). Estimated 3-year risk of any device therapy was 36% (24% appropriate, 12% inappropriate); for therapy requiring shock, corresponding values were 24%, 14%, 9%. The rate of appropriate therapy was higher in men than women (adjusted hazard ratio 1.84, 95% confidence interval 1.43-2.35). The rate of inappropriate therapy was higher for subjects &lt;65 than for those &gt;=65 years (1.40, 1.04-1.88), and lower among 2009 implants compared to 2006 (0.66, 0.46-0.95). Regarding the 3 CMS CED patient subgroups, neither ejection fraction nor heart failure symptom severity was associated with device therapy; for LVSD etiology, the rate of inappropriate therapy was nominally but not significantly higher among subjects with non-ischemic cardiomyopathy of &lt; 9 months duration (1.38, 0.88-2.18). Conclusions: In a representative cohort of primary prevention ICD patients in usual care, rates of device therapies were somewhat lower than in landmark trials, differed by some patient characteristics, but did not differ meaningfully for CMS CED subgroups.
Traumatic Brain Injury and Cases of Abnormal Menstrual Pattern—Reply
Authors: Meredith L. Snook, Anthony P. Kontos
Journal: JAMA Pediatrics (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t
Authors: M. de Bruin-Weller, D. Thaçi, C.H. Smith, K. Reich, M.J. Cork, A. Radin, Q. Zhang, B. Akinlade, A. Gadkari, L. Eckert, T. Hultsch, Z. Chen, G. Pirozzi, N.M.H. Graham, B. Shumel
Journal: British Journal of Dermatology (2017)

Atopic dermatitis is a chronic inflammatory skin disease that may require systemic therapy. Ciclosporin A (CsA) is a widely used, potent immunosuppressant but it is not effective in all patients with atopic dermatitis, and side‐effects limit its use. Dupilumab, a fully human anti‐interleukin 4 receptor‐alpha monoclonal antibody, inhibits signaling of IL‐4 and IL‐13, key drivers of Type 2/Th2‐mediated inflammation, and is approved in the U.S.A. and the European Union for the treatment of inadequately‐controlled moderate‐to‐severe atopic dermatitis in adults. To evaluate efficacy and safety of dupilumab with concomitant topical corticosteroids (TCS) in adults with atopic dermatitis with inadequate response to/intolerance of CsA, or for whom CsA treatment was medically inadvisable. In this 16‐week, double‐blind, randomized, placebo‐controlled, phase III trial, patients were randomized 1 : 1 : 1 to subcutaneous dupilumab 300 mg weekly (qw) or every 2 weeks (q2w) or placebo. All received concomitant medium‐potency TCS from Week −2 through Week 16; dosage could be tapered if lesions cleared, or stopped for adverse reactions to TCS. In total, 390 patients were screened, 325 were randomized, and 318 completed the trial. Treatment groups had similar baseline characteristics. Significantly more patients in the dupilumab qw + TCS and q2w + TCS groups achieved ≥ 75% improvement from baseline in the Eczema Area and Severity Index at Week 16 vs. the placebo + TCS group (primary end point) (59·1% and 62·6% vs. 29·6%, respectively; P < 0·001 vs. placebo + TCS, both doses). Other clinical outcomes and atopic dermatitis symptoms were significantly improved in the dupilumab qw + TCS and q2w + TCS groups, including pruritus, pain, sleep disturbance, symptoms of anxiety and depression, and quality of life (QoL). Treatment groups had similar overall rates of adverse events (qw + TCS, q2w + TCS and placebo + TCS groups: 69·1%, 72·0% and 69·4%, respectively) and serious adverse events (1·8%, 1·9% and 1·9%, respectively). Conjunctivitis was more frequent with dupilumab + TCS; skin infections were more frequent with placebo + TCS. Dupilumab + TCS significantly improved signs and symptoms of atopic dermatitis and QoL in adults with a history of inadequate response to/intolerance of CsA, or for whom CsA treatment was medically inadvisable. No new safety signals were identified.
Situação epidemiológica da BSE em França – actualização dos animais nascidos após os casos que levaram ao embargo
Authors: C Ducrot, D Calavas, T Baron, A E Agrech, M Coudert, M Savey
Journal: Eurosurveillance (2000)

Apesar das medidas tomadas em Franca, desde 1990, para controlar a disseminacao da encefalopatia espongiforme bovina (BSE), a incidencia dos casos de BSE notificados em Franca, pela Rede de Vigilância Epidemiologica da BSE, tem aumentado nos ultimos anos. Em 1 de Julho de 2000, tinham sido detectados 103 casos de BSE, incluindo 74 casos de ‘animais nascidos apos o embargo’ (ANAE). Este aumento expressa a evolucao da incidencia real da doenca e da vigilância da doenca.